Trust Signals
Standard: Every claim graded by evidence type. Speculation is labeled. No financial relationship with any referenced pharmacy or manufacturer.
Last reviewed: May 29, 2026.
Key Takeaways
- Gonadorelin is synthetic GnRH with a plasma half-life of roughly 2 to 4 minutes; HCG has a half-life of roughly 24 to 36 hours. That difference alone drives most practical protocol differences.
- HCG bypasses the pituitary entirely and acts directly on testicular LH receptors, which is both its strength (bypasses suppressed axis) and its limitation (no FSH activity at standard doses).
- The FDA restricted compounded HCG starting in 2020 under the BPCIA biologics framework, which is the primary regulatory reason gonadorelin use in TRT clinics grew rapidly.
- No published RCT has compared gonadorelin directly to HCG for testicular volume preservation or fertility outcomes in men on exogenous testosterone.
- At typical compounding doses (100 to 200 mcg subcutaneously), it is not yet confirmed that gonadorelin meaningfully overcomes testosterone-induced hypothalamic suppression in TRT patients.
Direct Answer: Gonadorelin vs HCG at a Glance
HCG has stronger human evidence for testicular preservation during testosterone therapy, a longer half-life that makes dosing convenient, and decades of fertility use behind it. Gonadorelin acts higher up the axis and adds FSH stimulation, but its extremely short half-life and unresolved suppression question in TRT users leave its real-world efficacy uncertain. Choose based on regulatory access, fertility goals, and individualized lab response.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How does each one work at the receptor level?
- What does the evidence actually show? (Evidence Ledger)
- Why is HCG now harder to prescribe in the US?
- What do most comparison pages get wrong?
- Honest head-to-head table
- Dosing and protocol: what the numbers actually look like
- Formulation, stability, and the reconstitution gotcha
- Label and COA literacy: how to judge a product yourself
- What if fertility is the actual goal?
- FAQ
- Sources
How Does Each One Work at the Receptor Level?
Gonadorelin is a synthetic decapeptide identical to endogenous GnRH. Its sequence is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. It binds GnRH receptors on anterior pituitary gonadotroph cells, triggering release of both LH and FSH via a G-protein coupled (Gq/11) pathway that activates phospholipase C, raises intracellular calcium, and causes granule exocytosis. The native hormone is released in pulses every 60 to 120 minutes; pulsatile administration preserves gonadotroph sensitivity, while continuous infusion paradoxically downregulates receptors. This is why GnRH agonists used in prostate cancer (leuprolide, etc.) cause testosterone suppression after an initial flare.
HCG is a glycoprotein hormone with an alpha subunit shared with LH, FSH, and TSH, and a beta subunit unique to HCG. The HCG beta subunit has an additional C-terminal peptide of 24 amino acids not found in LH, which accounts for its much longer half-life by reducing renal clearance. HCG binds the same testicular LH/CG receptor as endogenous LH (the LHCGR), stimulating Leydig cell production of intratesticular testosterone (ITT). ITT concentrations inside the testes are many times higher than serum testosterone, and this gradient is essential for spermatogenesis. HCG has essentially no FSH receptor affinity at standard doses.
The practical implication: If the pituitary is suppressed, HCG still works because it goes directly to the testis. Gonadorelin requires a functional pituitary response, which is increasingly uncertain when a man is on enough exogenous testosterone to suppress GnRH pulsatility at the hypothalamus.
What Does the Evidence Actually Show? (Evidence Ledger)
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| HCG prevents testicular atrophy during TRT | Small human RCTs and controlled studies (Coviello et al. 2005; Hsieh et al. 2013) | Positive: preserved testicular volume and ITT | Moderate |
| HCG maintains spermatogenesis during TRT | Controlled human studies (Hsieh et al. 2013, n=26 men on TRT) | Positive: sperm production maintained with 500 IU HCG 3x/week | Moderate |
| Gonadorelin stimulates LH and FSH in healthy volunteers | Human pharmacodynamic studies (established since 1970s; gonadorelin used diagnostically) | Positive: acute LH and FSH rise confirmed | High (for acute PD effect in non-suppressed men) |
| Gonadorelin preserves testicular function during exogenous testosterone administration | No published RCT; mechanistic inference only | Plausible but unconfirmed | Very Low |
| HCG LH receptor desensitization at clinical TRT-adjunct doses | Animal and in vitro data; human data limited | Possible at high/sustained doses; clinically uncertain at 500 IU 2x/week | Low |
| Gonadorelin subcutaneous absorption is sufficient for pituitary stimulation | Limited pharmacokinetic human data; route extrapolated from IV/intranasal studies | Probably absorbed; peak effect uncertain | Low |
| Adding HCG to TRT improves libido or mood vs TRT alone | Small RCT (Rahnema et al. review; Seftel 2012 data) | Mixed; some subjective improvement reported | Low |
Why Is HCG Now Harder to Prescribe in the US?
In 2020, FDA finalized its position that HCG is a biological product under the Biologics Price Competition and Innovation Act (BPCIA), not a drug. This classification removed HCG from the list of bulk drug substances that 503A compounding pharmacies can use without FDA approval. The result: compounded HCG became legally restricted for most retail compounding pharmacies, though FDA-approved HCG products (Novarel, Pregnyl) remain prescription-available. 503B outsourcing facilities face the same restriction for HCG.
This is a regulatory and access issue, not a safety or efficacy one. The clinical evidence for HCG did not change. Clinics pivoted to gonadorelin because it is a small synthetic peptide, not a biologic, and remains available through 503A compounding pharmacies. Understanding this context matters: the switch to gonadorelin was driven primarily by regulatory compounding access, not by evidence that gonadorelin works better.
What Do Most Comparison Pages Get Wrong?
They treat gonadorelin in a suppressed man the same as in a healthy man. This is the single largest error in the popular literature on this topic.
GnRH receptor stimulation depends on the pituitary gonadotrophs being responsive. In a healthy man, a 100 mcg IV bolus of gonadorelin reliably raises serum LH within 30 to 60 minutes. This is the basis for the gonadorelin stimulation test used diagnostically. But men on therapeutic doses of testosterone have suppressed hypothalamic GnRH tone. The question is whether exogenous subcutaneous gonadorelin at compounding doses can generate meaningful pulsatile stimulation of LH despite that upstream suppression, and more importantly, whether the resulting LH signal is sufficient to preserve Leydig cell mass and ITT levels.
No published controlled trial has answered this. Clinicians observe that some patients on gonadorelin maintain testicular size and LH does not fully zero out on labs, but this is anecdotal and uncontrolled.
They ignore the half-life problem. With a 2 to 4 minute plasma half-life, subcutaneous gonadorelin at 200 mcg produces a pulse that is cleared within minutes. Whether that brief pulse, given two or three times per week, is enough to maintain meaningful gonadotroph sensitization is an open question. Physiologic GnRH pulses occur every 60 to 120 minutes continuously. The analogy is not clean.
They omit FSH. HCG's lack of FSH activity is rarely discussed. Sertoli cells require FSH signaling for full spermatogenic support. In men on TRT where FSH is suppressed, HCG restores ITT but not FSH-driven Sertoli function. Gonadorelin, if it works, would stimulate FSH as well. This is a genuine potential advantage of gonadorelin for fertility, but it is theoretical in the context of TRT-level suppression.
Honest Head-to-Head Table
| Parameter | Gonadorelin | HCG | Edge |
|---|---|---|---|
| Mechanism | Pituitary GnRH receptor, drives LH and FSH | Testicular LHCGR, drives ITT directly | HCG more reliable in suppressed axis |
| Plasma half-life | Approx. 2 to 4 minutes | Approx. 24 to 36 hours | HCG: much easier dosing |
| Dosing frequency on TRT | 2 to 3x per week (common protocol) | 2x per week (common protocol) | HCG slightly simpler |
| FSH activity | Yes (if pituitary responds) | Essentially none at standard doses | Gonadorelin (theoretical) |
| Human evidence for testicular preservation on TRT | None (no RCT) | Moderate (multiple controlled studies) | HCG clearly |
| US compounding access | Available via 503A | Restricted (biologic classification) | Gonadorelin on access alone |
| Risk of gynecomastia | Low (indirect effect) | Moderate (aromatization of elevated ITT) | Gonadorelin |
| Risk of LH receptor downregulation | Low (targets pituitary) | Possible at high doses | Gonadorelin |
| Cost (compounded) | Generally lower per dose | Higher (pharmaceutical brand only in US) | Gonadorelin |
| Established fertility protocol data | Limited in TRT context | Extensive (decades of hypogonadism and fertility use) | HCG clearly |
Dosing and Protocol: What the Numbers Actually Look Like
Gonadorelin (compounding protocols): Most US clinics using gonadorelin for TRT adjunct prescribe 100 to 200 mcg subcutaneously two to three times per week. Some protocols align injections with TRT injection days. The rationale is to approximate pulsatile GnRH stimulation, though twice-weekly subcutaneous dosing is a rough extrapolation from IV pituitary stimulation studies. There is no FDA-approved dosing for this specific use. Practitioners monitor LH response on labs, though interpreting LH on TRT is complicated by testosterone's negative feedback.
HCG (standard TRT-adjunct protocols): Coviello et al. (2005) showed that 125 IU every other day and 500 IU every other day both maintained ITT above the threshold for spermatogenesis (estimated at roughly 50 nmol/L) in men on TRT. The 500 IU dose was more reliably effective. Hsieh et al. (2013) used 500 IU three times per week and showed sperm preservation in 26 men. Most clinical guidelines use 500 to 1500 IU two to three times per week. Higher doses above 1500 to 2000 IU increase estradiol through aromatization without proportional ITT benefit.
Monitoring: For HCG, check total testosterone, estradiol, and testicular volume or semen analysis if fertility is the goal. For gonadorelin, LH and FSH can be drawn, though values may be hard to interpret on testosterone therapy. Testicular volume by orchidometer is a practical surrogate endpoint for both.
Formulation, Stability, and the Reconstitution Gotcha
Gonadorelin stability: Gonadorelin is a decapeptide susceptible to hydrolysis, oxidation, and aggregation in solution. As a lyophilized powder, it is stable for months to years when stored at 2 to 8 degrees Celsius and protected from light. Once reconstituted in bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative), stability is generally cited as 28 days refrigerated by compounding pharmacies, but this is a conservative pharmacy practice standard rather than published stability kinetic data. Sterile water without a preservative should not be used for multi-dose vials because microbial growth risk is unacceptable over days.
Why the short half-life matters for formulation: Because gonadorelin clears in minutes, there is no slow-release standard formulation for this indication. Some researchers have explored microsphere or depot GnRH formulations, but these are experimental and not available through standard compounding. What you inject is what you get in that brief window.
HCG stability: Pharmaceutical HCG (Pregnyl, Novarel) comes lyophilized. Once reconstituted per package insert, refrigerated stability is typically 60 days for the diluent-reconstituted product, though this varies by product. Compounded HCG, before the regulatory restriction, faced the same 28-day convention. HCG is also sensitive to heat: a vial left at room temperature for extended periods can lose activity. The glycoprotein structure is more complex than a small peptide and can be denatured by agitation or temperature excursion.
The gotcha: Patients injecting reconstituted peptides at home often do not track reconstitution date. A vial of gonadorelin or HCG used at day 45 post-reconstitution may have substantially reduced potency with no visible change in the solution. Degradation is invisible. Date your vials on reconstitution, and discard per the pharmacy-labeled window.
Label and COA Literacy: How to Judge a Product Yourself
For gonadorelin from a compounding pharmacy:
- The label must state concentration (e.g., 1 mg/mL or 200 mcg/mL), lot number, expiration date, and dispensing pharmacy's 503A license number. Verify the pharmacy is PCAB-accredited or state-board inspected.
- Request a Certificate of Analysis (COA) showing HPLC purity (target above 95%), absence of residual solvents, and endotoxin testing. Peptide purity below 95% means a significant fraction of what you inject is degradation products or truncated sequences with unknown activity.
- Confirm the sequence on the COA matches the known gonadorelin/GnRH decapeptide. Some research-grade suppliers sell related peptides mislabeled.
For pharmaceutical HCG (Pregnyl, Novarel):
- These are FDA-approved biologics with potency measured in International Units (IU), standardized against a WHO reference preparation. The label IU is verified by bioassay, not just mass. This is a meaningful quality advantage over compounded peptides.
- Check that the vial and diluent are both present and sealed. The diluent provided is specific to the product's pH and osmolarity.
What If Fertility Is the Actual Goal?
If a man on TRT wants to father a child, the clinical evidence strongly favors HCG, often combined with FSH (recombinant FSH or human menopausal gonadotropin, hMG), not gonadorelin. The Schlegel and Sigman guidelines for male infertility recommend stopping exogenous testosterone and using HCG to restore ITT, with FSH added if sperm counts remain low after 3 to 6 months of HCG alone.
Gonadorelin as a fertility agent has a legitimate role in a specific scenario: men with hypothalamic hypogonadism (not TRT-induced) where the testes are intact and the pituitary is functional. Pulsatile GnRH infusion via pump is an established, evidence-backed treatment for this indication. That is a very different clinical situation from a healthy man whose axis is suppressed by exogenous testosterone.
If fertility is the goal during or after TRT, work with a reproductive endocrinologist. The evidence base is better for HCG-based protocols, and the decision to stay on or discontinue testosterone fundamentally changes the strategy.
FAQ
What is the main difference between gonadorelin and HCG?
Gonadorelin acts on the pituitary to stimulate LH and FSH release, preserving the full HPG axis. HCG bypasses the pituitary and acts directly on the testicular LH receptor, stimulating testosterone and sperm production without engaging FSH pathways at standard doses.
Is gonadorelin or HCG better for fertility on TRT?
HCG has substantially more human fertility data. It drives intratesticular testosterone production, which is necessary for spermatogenesis, and decades of clinical use support this. Gonadorelin's fertility benefit on TRT is biologically plausible but lacks comparative trial data.
Why did HCG become harder to prescribe in the US?
The FDA withdrew the use of compounded HCG from the 503A/503B compounding exemption in 2020, citing its status as a biologic under the BPCIA. This made pharmacy-compounded HCG legally restricted, pushing many clinics toward gonadorelin as an alternative.
What is the half-life of gonadorelin compared to HCG?
Gonadorelin has a plasma half-life of roughly 2 to 4 minutes, requiring subcutaneous injections several times per week or more to maintain pituitary stimulation. HCG has a much longer half-life of approximately 24 to 36 hours, allowing twice-weekly or even weekly dosing.
Can gonadorelin raise FSH where HCG cannot?
Yes. Gonadorelin stimulates both LH and FSH release from the pituitary. HCG has essentially no FSH activity at standard clinical doses. For men where FSH-driven Sertoli cell support is needed, gonadorelin or adding FSH injections would be required.
Does gonadorelin actually work when you are suppressed on TRT?
This is the critical unresolved question. Exogenous testosterone suppresses GnRH pulsatility at the hypothalamus. Whether subcutaneous gonadorelin at compounding doses can overcome that suppression and generate meaningful LH pulses in TRT users is not yet confirmed by controlled trials.
What are the side effects of HCG vs gonadorelin?
HCG can cause fluid retention, gynecomastia risk from aromatization of intratesticular testosterone, and mood effects. Gonadorelin side effects at subcutaneous doses are generally mild, with injection site reactions most common. Systemic reactions are rare at low compounding doses.
How do you dose gonadorelin on TRT?
Clinical protocols used in compounding contexts typically range from 100 to 200 mcg subcutaneously two to three times per week. This is extrapolated from pituitary stimulation studies, not from RCTs in TRT users. There is no FDA-approved dosing protocol for this indication.
Is gonadorelin the same as GnRH?
Yes. Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. It is identical in structure to the naturally occurring hypothalamic hormone.
Does HCG cause desensitization of LH receptors?
Sustained, high-dose HCG exposure can downregulate testicular LH receptors in animal and in vitro models. Whether standard clinical TRT-adjunct doses (500 to 1500 IU twice weekly) cause clinically meaningful desensitization in humans is debated and not definitively established by trial data.
How should gonadorelin be stored and reconstituted?
Lyophilized gonadorelin powder should be refrigerated at 2 to 8 degrees Celsius and reconstituted with bacteriostatic water. Once reconstituted, it should be used within 28 days if refrigerated. Exposure to light and heat accelerates peptide bond degradation.
Which is cheaper, gonadorelin or HCG?
Compounded gonadorelin is generally less expensive per dose than pharmaceutical HCG (such as Novarel or Pregnyl) when obtained through a 503A compounding pharmacy. However, price varies significantly by pharmacy and prescription structure.
Sources
- Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2595-2602.
- Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology. 2013;189(2):647-650.
- Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinology and Metabolism Clinics of North America. 1994;23(4):857-875.
- Knobil E. The neuroendocrine control of the menstrual cycle. Recent Progress in Hormone Research. 1980;36:53-88. (Foundational pulsatile GnRH physiology.)
- FDA. Bulk Drug Substances That May Be Used in Pharmacy Compounding (503A): HCG biologic classification. Federal Register, 2020. Docket FDA-2019-N-5711.
- Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertility and Sterility. 2014;101(5):1271-1279.
- Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173(4001):1036-1038.
- Spratt DI, Crowley WF Jr, Butler JP, Hoffman AR, Conn PM, Badger TM. Pituitary LH and FSH responses to single doses of GnRH. American Journal of Physiology. 1985;248(4 Pt 1):E458-E464.
- Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertility and Sterility. 2021;115(1):54-61.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744.